AIM ImmunoTech (AIM) Restructuring Costs (2016 - 2019)

AIM ImmunoTech's (AIM) quarterly Restructuring Costs came in at $1.5 million in Q4 2019, up 668.08% on a QoQ basis from -$260000.0 in Q2 2019.

AIM ImmunoTech (AIM) Restructuring Costs (2016 - 2019) Analysis & Trends

AIM ImmunoTech (AIM) has 3 years of Restructuring Costs data on file, last reported at $1.5 million in Q4 2019.

Quarterly Restructuring Costs changed N/A year-over-year to $1.5 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $1.2 million (up 283.28% YoY) and the FY2019 annual result came in at $1.2 million, up 356.75% from the prior year.
Restructuring Costs grew to $1.5 million in Q4 2019, from -$260000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $1.5 million in Q4 2019 to a low of -$1.4 million in Q2 2016.
A 3-year average of -$176600.0 and a median of -$260000.0 in 2019 frame the typical range for Restructuring Costs.
The widest YoY moves for Restructuring Costs: up 45.15% in 2019, down 45.15% in 2019.
Tracing AIM's Restructuring Costs over 3 years: stood at -$190000.0 in 2016, then tumbled by 149.47% to -$474000.0 in 2018, then jumped by 411.6% to $1.5 million in 2019.
The last three Restructuring Costs figures came in at $1.5 million (Q4 2019), -$260000.0 (Q2 2019), and -$474000.0 (Q2 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	AIM ImmunoTech	4.34 Mn	-5.62 Mn	21,000.00

Download Data